Drug Discovery Today

Results: 21



#Item
11May 25, 2010 Announcement of New Mid-Term Management Plan Japan, May 25, 2010 —Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) today announced the new five-year mid-ter

May 25, 2010 Announcement of New Mid-Term Management Plan Japan, May 25, 2010 —Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) today announced the new five-year mid-ter

Add to Reading List

Source URL: www.astellas.com

Language: English - Date: 2010-05-25 01:40:44
12M E D I A I N F O R M AT I O N[removed]For more information visit: www.drugdiscoverytoday.com/mediakit Why choose Drug

M E D I A I N F O R M AT I O N[removed]For more information visit: www.drugdiscoverytoday.com/mediakit Why choose Drug

Add to Reading List

Source URL: advertising.drugdiscoverytoday.com

Language: English - Date: 2013-12-19 12:40:56
13Gov. Malloy: State To Support Cutting-Edge Biotech Startup New Haven-based Company Is Developing Cancer Fighting Drugs (HARTFORD, CT) – Governor Dannel P. Malloy today announced $4.25 million in state support for Arvin

Gov. Malloy: State To Support Cutting-Edge Biotech Startup New Haven-based Company Is Developing Cancer Fighting Drugs (HARTFORD, CT) – Governor Dannel P. Malloy today announced $4.25 million in state support for Arvin

Add to Reading List

Source URL: www.ct.gov

Language: English - Date: 2013-09-27 11:48:44
14BIOWORLD TODAY TM THE DAILY BIOPHARMACEUTICAL NEWS SOURCE BIOTECH’S MOST RESPECTED NEWS SOURCE FOR MORE THAN 20 YEARS

BIOWORLD TODAY TM THE DAILY BIOPHARMACEUTICAL NEWS SOURCE BIOTECH’S MOST RESPECTED NEWS SOURCE FOR MORE THAN 20 YEARS

Add to Reading List

Source URL: www.ccrm.ca

Language: English - Date: 2014-05-27 13:10:31
15Published in Drug Discovery Today, Volume 10, Issue 6, Pages[removed]March[removed]Text Mining: Getting more value from literature resources Roger Hale, Chief Operating Officer, Linguamatics Ltd Scientists in the phar

Published in Drug Discovery Today, Volume 10, Issue 6, Pages[removed]March[removed]Text Mining: Getting more value from literature resources Roger Hale, Chief Operating Officer, Linguamatics Ltd Scientists in the phar

Add to Reading List

Source URL: www.linguamatics.com

Language: English - Date: 2011-01-09 03:24:01
16e-Therapeutics’ full year results for the 12 months ended 31 January[removed]May 2014: e-Therapeutics plc (AIM: ETX), the drug discovery and development company, today announces its full year results for the 12 months

e-Therapeutics’ full year results for the 12 months ended 31 January[removed]May 2014: e-Therapeutics plc (AIM: ETX), the drug discovery and development company, today announces its full year results for the 12 months

Add to Reading List

Source URL: www.etherapeutics.co.uk

Language: English - Date: 2014-06-17 10:22:19
17e-Therapeutics announces recruitment resumes into US phase I ETS2101 brain cancer trial Oxford and Newcastle, UK, 8 May[removed]e-Therapeutics plc (AIM:ETX) announces today that the US Food and Drug Administration (FDA) h

e-Therapeutics announces recruitment resumes into US phase I ETS2101 brain cancer trial Oxford and Newcastle, UK, 8 May[removed]e-Therapeutics plc (AIM:ETX) announces today that the US Food and Drug Administration (FDA) h

Add to Reading List

Source URL: www.etherapeutics.co.uk

Language: English - Date: 2014-06-17 10:17:12
18e-Therapeutics announces recruitment resumes into UK phase I ETS2101 cancer trial Oxford and Newcastle, UK, 26 March[removed]e-Therapeutics plc (AIM:ETX) announces today that it has received approval from MHRA to recommen

e-Therapeutics announces recruitment resumes into UK phase I ETS2101 cancer trial Oxford and Newcastle, UK, 26 March[removed]e-Therapeutics plc (AIM:ETX) announces today that it has received approval from MHRA to recommen

Add to Reading List

Source URL: www.etherapeutics.co.uk

Language: English - Date: 2014-06-17 10:17:11
19e-Therapeutics Begins Phase I Study of Oral Formulation of Anti-Cancer Compound ETS2101 with Healthy Volunteers 10 February 2014 – e-Therapeutics plc (AIM:ETX) announced today that it has dosed the first healthy volunt

e-Therapeutics Begins Phase I Study of Oral Formulation of Anti-Cancer Compound ETS2101 with Healthy Volunteers 10 February 2014 – e-Therapeutics plc (AIM:ETX) announced today that it has dosed the first healthy volunt

Add to Reading List

Source URL: www.etherapeutics.co.uk

Language: English - Date: 2014-06-17 10:24:01
20Naurex to Present at Cowen and Co. 34th Annual Health Care Conference EVANSTON, Ill. – Feb. 27, 2014 – Naurex Inc. today announced that its president and chief executive officer, Norbert G. Riedel, Ph.D., will presen

Naurex to Present at Cowen and Co. 34th Annual Health Care Conference EVANSTON, Ill. – Feb. 27, 2014 – Naurex Inc. today announced that its president and chief executive officer, Norbert G. Riedel, Ph.D., will presen

Add to Reading List

Source URL: naurex.com

Language: English - Date: 2014-02-27 15:32:41